Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresec…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05677490
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
- Sibley Memorial Hospital — Washington D.C., District of Columbia
- George Washington University Medical Center — Washington D.C., District of Columbia
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from wh…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06203600
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in District of Columbia: - Research Site — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
Sponsor: AstraZeneca
NCT ID: NCT06346392
Sites in District of Columbia: - Research Site — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2…
Sponsor: RayzeBio, Inc.
NCT ID: NCT05477576
Sites in District of Columbia: - Research Facility — Washington D.C., District of Columbia
Phase 3 Recruiting Academic/Other
This study is a non-randomized, open-label, multi-cohort, multi-site, pilot feasibility therapeutic trial. The study will enroll 20 patients across 4 cohorts (CRC, gastric, PDAC, and HCC/intra-hepatic-/extra-hepatic-, gall bladder adenocar…
Sponsor: Georgetown University
NCT ID: NCT05482516
Sites in District of Columbia: - Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
- Medstar Washington Hospital Center — Washington D.C., District of Columbia
Phase 2 Recruiting Industry
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're …
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT06157892
Sites in District of Columbia: - Georgetown University Medical Center — Washington D.C., District of Columbia
- MedStar Georgetown University Hospital — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in District of Columbia: - Washington Cancer Institute at MedStar Washington Hospital Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study. This study aims to assess the a…
Sponsor: EMD Serono Research & Development Institute, Inc.
NCT ID: NCT06710132
Sites in District of Columbia: - Georgetown University - Lombardi Comprehensive Cancer Center - 1134847 — Washington D.C., District of Columbia
Phase 2 Recruiting Industry
GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastri…
Sponsor: AstraZeneca
NCT ID: NCT07069712
Sites in District of Columbia: - Research Site — Washington D.C., District of Columbia
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in District of Columbia: - John Hopkins Kimmer Cancer Center — Washington D.C., District of Columbia
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
Recruiting Academic/Other
The Cancer Experience Registry®: An Online Survey Research Study to Understand the Experiences of Those Impacted By a Cancer Diagnosis. The Registry is a web-based platform to distribute cross-sectional and longitudinal surveys. Study surv…
Sponsor: Cancer Support Community, Research and Training Institute, Philadelphia
NCT ID: NCT02333604
Sites in District of Columbia: - Cancer Support Community Research & Training Institute — Washington D.C., District of Columbia